Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors

Journal of Cardiovascular Medicine

Volumn 14, Issue 11, 2013, Pages 815-820

  De Luca, Giuseppe ^a   Gibson, Michael C ^b   Hof, Arnoud W J Van'T ^c   Cutlip, Donald ^d   Zeymer, Uwe ^g   Noc, Marko ^e   Maioli, Mauro ^f   Zorman, Simona ^e   Gabriel, Mesquita H ^h   Secco, Gioel Gabrio ^a   Emre, Ayse ⁱ   Dudek, Dariusz ^j   Rakowski, Tomasz ^j   Gyongyosi, Maryann ^k   Huber, Kurt ^l   Bellandi, Francesco ^f  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOSPITAL DE WEEZENLANDEN   (Netherlands)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^f Prato Hospital   (Italy)

^g KLINIKUM LUDWIGSHAFEN   (Germany)

^h HOSPITAL DE SANTA MARIA   (Portugal)

ⁱ DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^j JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l WILHELMINEN HOSPITAL   (Austria)

more..

Author keywords

Gp IIb IIIa; myocardial perfusion; ST segment elevation myocardial infarction; time to treatment

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ADULT; ANGIOPLASTY; ARTICLE; CORONARY STENT; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TIME TO TREATMENT;

AGE FACTORS; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CREATINE KINASE; CREATINE KINASE, MB FORM; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SEX FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84885382740     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32835fcb38     Document Type: Article

References (38)

1. De Luca G, Cassetti E, Marino P. Percutaneous coronary interventionrelated time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 2009; 27:712-719.
2. De Luca G, Biondi-Zoccai G, Marino P. Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials. Ann Emerg Med 2008; 52:665-676.
3. Di Lorenzo E, Sauro R, Varricchio A, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J 2009; 158:e43-e50.
4. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293:1759-1765.
5. De Luca G, Navarese E, Marino P. Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials. Eur Heart J 2009; 30:2705-2713.
6. De Luca G, Ucci G, Cassetti E, Marino P. Benefits from small molecule administration as compared with abciximab among patients with STsegment elevation myocardial infarction treated with primary angioplasty: a meta-analysis. J Am Coll Cardiol 2009; 53:1668-1673.
7. De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart 2008; 94:1548-1558.
8. De Luca G, Dudek D, Sardella G, et al. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 2008; 29:3002-3010.
9. De Luca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials. Thromb Haemost 2009; 102:428-436.
10. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996; 27:1646-1655.
11. Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23:550-557.
12. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32:1312-1319.
13. Berger B, Ellis SG, Holmes DR, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO IIb) trial. Circulation 1999; 100:14-20.
14. Cannon GP, Gibson GM, Lambrew CT, et al. Relationship of symptomonset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283:2941-2947.
15. Schö mig A, Ndrepepa G, Mehilli J, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation 2003; 108:1084-1088.
16. Ndrepepa G, Kastrati A, Schwaiger M, et al. Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. J Nucl Med 2005; 46:1782-1788.
17. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109:1223-1225.
18. De Luca G, Suryapranata H, Zijlstra F, et al., ZWOLLE Myocardial Infarction Study Group. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003; 42:991-997.
19. De Luca G, Ernst N, Suryapranata H, et al. Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty. Am J Cardiol 2005; 95:1361-1363.
20. Maeng M, Nielsen PH, Busk M, et al., DANAMI-2 Investigators. Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) substudy. Am J Cardiol 2010; 105:1528-1534.
21. De Luca G, van 't Hof AW, Ottervanger JP, et al. Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Am Heart J 2005; 150:557-562.
22. De Luca G, Suryapranata H, de Boer MJ, et al. Impact of vessel size on distal embolization, myocardial perfusion and clinical outcome in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. J Thromb Thrombolysis 2009; 27:198-203.
23. De Luca G, van't Hof AW, de Boer MJ, et al. Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J 2004; 25:1009-1013.
24. Brodie BR, Webb J, Cox DA, et al., EMERALD Investigators. Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). Am J Cardiol 2007; 99:1680-1686.
25. Stone GW, Dixon SR, Grines CL, et al. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. Am J Cardiol 2007; 100:1370-1375.
26. Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 2005; 46:1229-1235.
27. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367:569-578.
28. De Luca G, Marino P. Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Am J Emerg Med 2009; 27:683-690.
29. Ellis SG, Tendera M, de Belder MA, et al., FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358:2205-2217.
30. Herrmann HC, Lu J, Brodie BR, et al., FINESSE Investigators. Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. JACC Cardiovasc Interv 2009; 2:917-924.
31. Ellis SG, Tendera M, de Belder MA, et al., FINESSE Investigators. 1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. JACC Cardiovasc Interv 2009; 2:909-916.
32. Silvain J, Collet JP, Nagaswami C, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57:1359-1367.
33. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost 2011; 9:2361-2370.
34. Dudek D, Siudak Z, Janzon M, et al., EUROTRANSFER Registry Investigators. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab: EUROTRANSFER Registry. Am Heart J 2008; 156:1147-1154.
35. Ortolani P, Marzocchi A, Marrozzini C, et al. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network. Eur Heart J 2009; 30: 33-43.
36. Hassan AK, Liem SS, van der Kley F, et al. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! Acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv 2009; 74:335-343.
37. Huber K, Holmes DR Jr, van 't Hof AW, et al. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. Eur Heart J 2010; 31:1708-1716.
38. Van de Werf F, Bax J, Betriu A, et al., ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909-2945.